Clinical Trials Logo

Citation(s)

  •   Vilsboll T, Lindahl CO, Nielsen NF, Tikkanen CK
    Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes. Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15031. Online ahead of print.

A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes

Details for clinical trial NCT04261933